PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update - New Market Report
GlobalData has released its new Country report, "PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update". The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and...
View full press release